Impact of type 2 diabetes on complications after primary breast cancer surgery: Danish population-based cohort study
Open Access
- 2 March 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 111 (3)
Abstract
Background: Knowledge is sparse on the impact of type 2 diabetes (T2D) on surgical outcomes after breast cancer surgery. This study investigated the association between T2D and risk of complications after primary breast cancer surgery, and evaluated the biological interaction between T2D and co-morbidities. Methods: Using the Danish Breast Cancer Group clinical database, a cohort of all Danish women diagnosed with early-stage breast cancer during 1996–2022 was created. All patients underwent mastectomy or breast-conserving surgery. Information on prevalent T2D was collected from Danish medical and prescription registries. Surgical complications were defined as hospital diagnoses for medical or surgical complications developing within 30 days after primary breast cancer surgery. The 30-day cumulative incidence proportion of complications was calculated, and Cox regression was used to estimate HRs. Interaction contrasts were computed to determine the additive interaction between T2D and co-morbidities on the incidence rate of complications. Results: Among 98 589 women with breast cancer, 6332 (6.4%) had T2D at breast cancer surgery. Overall, 1038 (16.4%) and 9861 (10.7%) women with and without T2D developed surgical complications, yielding cumulative incidence proportions of 16 (95% c.i. 15 to 17) and 11 (10 to 11)% respectively, and a HR of 1.43 (95% c.i. 1.34 to 1.53). The incidence rate of surgical complications explained by the interaction of T2D with moderate and severe co-morbidity was 21 and 42%, respectively. Conclusion: Women with breast cancer and T2D had a higher risk of complications after primary breast cancer surgery than those without T2D. A synergistic effect of T2D and co-morbidity on surgical complications can explain this association.Keywords
Funding Information
- Novo Nordisk Foundation (NNF20OC0065928)
- Danish Cancer Society (R328-A19070, R247-A14719)
- Riisfort Foundation
This publication has 46 references indexed in Scilit:
- Increased morbidity evaluated on hospital contacts and prescriptions among 100,834 Danish breast cancer survivorsJournal of Cancer Research and Clinical Oncology, 2022
- Impact of Body Mass Index on Outcomes After Breast Cancer Surgery: Nationwide Inpatient Database Study in JapanClinical Breast Cancer, 2020
- Breast cancer extent and survival among diabetic women in a Finnish nationwide cohort studyInternational Journal of Cancer, 2018
- Economic impact of bleeding complications after mastectomyJournal of Surgical Research, 2015
- The association between diabetes and breast cancer stage at diagnosis: a population-based studyBreast Cancer Research and Treatment, 2015
- Neoadjuvant Chemotherapy and Short-term Morbidity in Patients Undergoing Mastectomy With and Without Breast ReconstructionJAMA Surgery, 2014
- The Danish Civil Registration System as a tool in epidemiologyEuropean Journal of Epidemiology, 2014
- Predictors of re-operation due to post-surgical bleeding in breast cancer patients: A Danish population-based cohort studyEuropean Journal of Surgical Oncology, 2012
- Multiple imputation using chained equations: Issues and guidance for practiceStatistics in Medicine, 2010
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987